24th week of 2021 patent applcation highlights part 11 |
Patent application number | Title | Published |
20210177920 | BACTERIOPHAGE TREATMENT FOR ACNE AND BIOFILMS - Bacteriophage compositions and therapeutic uses thereof. In particular, compositions of lytic bacteriophages that are capable of lysing | 2021-06-17 |
20210177921 | TARGETING MOIETY-DECORATED ONCOLYTIC VIRUSES - Compositions and methods are provided for treating cancer comprising a composition comprising an oncolytic virus and a targeting moiety on the surface of the virus, wherein the oncolytic virus does not encode or express the targeting moiety within various aspects such compositions and methods can be used to treat a wide variety of cancers (e.g., gastrointestinal cancer, such as esophageal, stomach and colon cancers). | 2021-06-17 |
20210177922 | PROCESS FOR PRODUCING A CANNABIS TINCTURE OR SALVE - Processes for producing a | 2021-06-17 |
20210177923 | PANAX PLANT EXTRACT AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2021-06-17 |
20210177924 | CANNABIS AND BUTTERFLY PEA EXTRACT - A formulation includes butterfly pea extract and cannabinoids. | 2021-06-17 |
20210177925 | A SYNERGISTIC COMPOSITION AS A PROMOTER OF AUTOPHAGY - The invention relates to a synergistic composition comprising a dry extract of plant of genus | 2021-06-17 |
20210177926 | HERBAL MEDICINE EXTRACTS AND USES AND METHODS OF PREPARATION THEREOF - The present invention provides a composition of a mixture comprising | 2021-06-17 |
20210177927 | FINE BAMBOO POWDER AND PREPARATION METHOD THEREFOR AND USE THEREOF - A MATZHU is prepared by using leaves of Gramineae (Graminae) and Bambusoideae plant as raw materials. The MATZHU has a stable emerald color and an average powder particle size of 800 to 10,000 meshes. The MATZHU also has a total amount of dietary fiber of ≥60%, a content of lignin of ≥20% and a content of minerals of ≥7%. The MATZHU includes at least three or more bamboo leaf characteristic components, such as orientin, isoorientin, vitexin, isovitexin, adenosine, δ-hydroxylysine and p-coumaric acid. The method for the MATZHU preparation includes, in turn, performing blanching and color protection, drying and superfine grinding the raw materials. By utilizing the thermal stability and the light stability of the MATZHU, the MATZHU may be used as a raw food material, a functional ingredient, or a dietary supplement. | 2021-06-17 |
20210177928 | Method of Reducing Titers of Antibodies Specific for a Therapeutic Agent - The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods. | 2021-06-17 |
20210177929 | NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF - A conjugate and preparation method therefor, comprising a medication composition comprising the conjugate and a use of the medication composition in preparing medications for the treatment or prevention of diseases. | 2021-06-17 |
20210177930 | COMPOSITION FOR USE IN IMPROVING ATTENTION FUNCTION AND JUDGEMENT FUNCTION - An object of the present invention is to provide a composition for use in improving, maintaining and/or ameliorating an attention function and/or a judgement function. According to the present invention, there is provided a composition for use in improving, maintaining and/or ameliorating an attention function and/or a judgement function, comprising an enzymatic decomposition product of milk protein as an active ingredient. The enzymatic decomposition product of milk protein is preferably an enzymatic decomposition product of whey protein. The enzymatic decomposition product of milk protein preferably comprises a peptide having an amino acid sequence of GTWY (SEQ ID NO: 1) and a peptide having an amino acid sequence of WY. | 2021-06-17 |
20210177931 | ANTICANCER PEPTIDES THAT SYNERGISTICALLY ENHANCE CHEMOTHERAPEUTIC POTENCY - Provided is a method for treating cancer by administering to an individual who has the cancer a MAD1 peptide. The peptide can enhance the effect of a chemotherapeutic agent that is administered to the individual in combination with the peptide. | 2021-06-17 |
20210177932 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE DEFICIENCY AND INFLAMMATION - Disclosed herein are compositions and methods for the prevention and treatment of immune deficiency and inflammation using cyclic histidyl-proline plus zinc (Cyclo-Z). Disclosed herein are compositions that can be used to treat immune disorders and inflammation. | 2021-06-17 |
20210177933 | Method of treating ophthalmic conditions - Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed. | 2021-06-17 |
20210177934 | METHOD OF TREATING OPHTHALMIC CONDITIONS - Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed. | 2021-06-17 |
20210177935 | METHOD OF TREATING OPHTHALMIC CONDITIONS - Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed. | 2021-06-17 |
20210177936 | METHODS, REAGENTS AND KITS FOR DETECTING MINIMAL RESIDUAL DISEASE - The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≥8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10 | 2021-06-17 |
20210177937 | COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION - Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8 | 2021-06-17 |
20210177938 | TISSUE CATALYZED GROWTH OF POLYMER AS EPITHELIAL LININGS FOR THERAPY - The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder. | 2021-06-17 |
20210177939 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site. | 2021-06-17 |
20210177940 | TREATMENT AND PREVENTION OF METABOLIC DISEASES - Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods. | 2021-06-17 |
20210177941 | COMPOSITIONS FOR CHANGING BODY COMPOSITION, METHODS OF USE, AND METHODS OF TREATMENT - The present disclosure provides compositions including an amylin receptor agonist and a beta-2-adreno-receptor agonist (e.g., an anti-hyperglycemia agent), compositions including at least two different anti-catabolic agents, compositions including at least two different anti-adiposity agents, methods of treating a condition (e.g., muscle wasting, muscle wasting-related condition, excess adiposity, an excess adiposity-related condition, and the like), methods of increasing muscle mass, formation of thermogenic brown adipose tissue (BAT), and/or decreasing white adipose tissue (WAT) content, methods of treating muscle wasting, methods of treating excess adiposity, and the like. | 2021-06-17 |
20210177942 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES - The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L | 2021-06-17 |
20210177943 | GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE - The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH | 2021-06-17 |
20210177944 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID - The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine. | 2021-06-17 |
20210177945 | PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HGH FOR THE TREATMENT OF GROWTH HORMONE DEFICIENCY - Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. | 2021-06-17 |
20210177946 | THERAPEUTIC MEDICATIONS FOR THE SPHENOPALATINE GANGLION - Disclosed herein are methods and compositions for treatment of neurological-related disorders, and pain syndrome associated with disorders using botulinum toxin targeted to nerve ganglia. | 2021-06-17 |
20210177947 | SKIN THERAPEUTICS - Disclosed herein are methods and compositions for treatment of skin disorders and diseases using botulinum toxin targeted to nerve ganglia. It has been unexpectedly found that botulinum neurotoxin (BoNT) can decrease the severity of numerous skin disorders by application to nerve ganglia including but not limited to the parasympathetic, sympathetic, and sensory ganglia | 2021-06-17 |
20210177948 | Antimalarial Enzyme Conjugates, Kits Containing Same, and Methods of Producing and Using Same - A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with | 2021-06-17 |
20210177949 | NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION - The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. | 2021-06-17 |
20210177950 | Methods Of Preparing Cancer Treatments And Methods Of Treating Cancer - Methods for preparing antigen-loaded dendritic cells (DCs) for treatment of cancer in a subject are provided, using an electroporation apparatus having an electroporation chamber including an upper electrode, a lower electrode and a path defined in the electroporation chamber. The electroporation apparatus includes a first input allowing passage of DCs into the electroporation chamber and a first output allowing passage of antigen-loaded DCs from the electroporation chamber. The first input and the first output are separated by an offset distance. Methods of treating cancer by administering antigen-loaded DCs are also provided. | 2021-06-17 |
20210177951 | ENGINEERED CELLS & METHODS - The present invention relates to engineered cells, engineered chimaeric antigen ligands (CALs), and novel uses of multi-specific binding agents for bridging cells. The invention also provides variation-matched engineered cells. | 2021-06-17 |
20210177952 | METHOD AND COMPOSITION FOR STIMULATING IMMUNE RESPONSE - A composition for administration to a subject is disclosed and the composition comprises a vaccine and plinabulin without or with an adjuvant to induce, enhance or boost humoral response. A method of treatment by administering a vaccine and plinabulin is disclosed. A method of enhancing an immune response to a vaccine in a subject by administering to the subject a vaccine and plinabulin is also disclosed. The vaccine and plinabulin can be administered concurrently or separately. | 2021-06-17 |
20210177953 | Engineered Non-Human Derived Immune Cells for Universal Adoptive Antigen Cellular Immunotherapy - This invention relates to non-human immune cells for universal chimeric antigen receptor and related immune cell therapies. | 2021-06-17 |
20210177954 | NEOANTIGENS AND USES THEREOF - Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions. | 2021-06-17 |
20210177955 | IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOF - Provided herein are tumor-associated antigen peptides comprising heteroclitic mutations and fusion polypeptides comprising such heteroclitic peptide. Also provided are nucleic acids encoding such peptides and fusion polypeptides, recombinant bacteria or | 2021-06-17 |
20210177956 | SELF-ADJUVANTING YERSINIA OUTER MEMBRANE VESICLE AS A VACCINE AGAINST PLAGUE, ANTHRAX AND PSEUDOMONAS INFECTION - A vaccine platform using a | 2021-06-17 |
20210177957 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF - The invention is related to multivalent immunogenic compositions comprising more than one | 2021-06-17 |
20210177958 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME - The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof. | 2021-06-17 |
20210177959 | METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION - The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation. | 2021-06-17 |
20210177960 | RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS STRAINS COMPRISING NS1 AND NS2 GENE SHIFTS - Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses. | 2021-06-17 |
20210177961 | FELINE LEUKEMIA VIRUS VACCINE - The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents. | 2021-06-17 |
20210177962 | MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION - In one embodiment, an expression system for expressing a UL128 complex is provided herein. The expression system may include a bacterial artificial chromosome (BAC) construct, wherein the BAC construct comprises a viral vector inserted with a set of DNA sequences that encode a UL128 complex. In another embodiment, a vaccine composition for preventing HCMV infection is provided. The vaccine composition may include a viral or bacterial vector capable of expressing a UL128 complex and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof or additional vector expressing a protein adjuvant. The viral vector may be an MVA and the UL128 complex includes five HCMV proteins or antigenic fragments thereof: UL128, UL130, UL131A, gL, and gH. In some embodiments, the viral vector is further inserted with one or more additional DNA sequences that encode one or more additional HCMVHCMV proteins or antigenic fragments thereof such as pp65, gB or both, or such as gM/gN or gO. | 2021-06-17 |
20210177963 | Method and System for Protecting Honey Bees from Pesticides - A method and system for the treatment of honey bees ( | 2021-06-17 |
20210177964 | HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT - The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) vims (Heat-iMVA) or Heat-inactivated vaccinia vims as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies for use as a cancer immunotherapeutic. | 2021-06-17 |
20210177965 | BRARTEMICIN ANALOGUES - The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants. | 2021-06-17 |
20210177966 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS - The disclosure relates to novel regimens for treating an inflammatory arthiritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). | 2021-06-17 |
20210177967 | APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS - The disclosure provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The disclosure also features kits for carrying out the methods. | 2021-06-17 |
20210177968 | DERMAL APPLICATOR FOR USE IN CANCER PHOTOIMMUNOTHERAPY - Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means. | 2021-06-17 |
20210177969 | BIOPHOTONIC COMPOSITIONS COMPRISING A CHROMOPHORE AND A GELLING AGENT FOR TREATING WOUNDS - The present disclosure provides biophotonic compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure arc substantially resistant to leaching such that low amounts of chromophores present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting repair of non-healing wounds. | 2021-06-17 |
20210177970 | Multifunctional Treatment And Diagnostic Compositions And Methods - Multifunctional compositions and methods are provided for therapeutic treatment of bacteria and cancers and for fluorescence diagnosis. Systems generate in situ reactive oxygen species such as singlet oxygen ( | 2021-06-17 |
20210177971 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-06-17 |
20210177972 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-06-17 |
20210177973 | FLUORESCEIN AND BENOXINATE COMPOSITIONS - Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage. | 2021-06-17 |
20210177974 | BIODEGRADABLE LIQUOGEL AND PH SENSITIVE NANOCARRIERS - A delivery system using materials that form a liquogel or nanocarrier are described. The delivery system comprises hyperbranched polyglycerols (HPGs). The delivery system can include a drug or therapeutic agent and this system can be used to administer the drug or therapeutic agent locally. The delivery system provides for controlled release of the drug or therapeutic agent. | 2021-06-17 |
20210177975 | MEDICAL ORGANOGEL PROCESSES AND COMPOSITIONS - Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking. | 2021-06-17 |
20210177976 | STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE - Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C. | 2021-06-17 |
20210177977 | Shape Memory Silk Materials - The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials. | 2021-06-17 |
20210177978 | METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS - Aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents. More particularly, aspects described herein relate to improved methods for infusing food and beverage compositions with lipophilic active agents using tapioca starch or related compounds. Lipophilic active agents include cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins. | 2021-06-17 |
20210177979 | NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS - Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis. | 2021-06-17 |
20210177980 | PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF - Disclosed herein are porcine interferon alpha variants (pINF-α) comprising a synthetic amino acid at select locations in pINF-α and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-α variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided. | 2021-06-17 |
20210177981 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY - The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation. | 2021-06-17 |
20210177982 | MUCUS-PENETRATING PEPTIDES, DELIVERY VEHICLES AND METHODS OF THERAPY - Provided are compositions including delivery vehicles with at least one mucus-penetrating property and mucus-penetrating peptides. Also disclosed are such compositions including a cargo and methods of making and using the same. | 2021-06-17 |
20210177983 | SINGLE CHAIN Fc FUSION PROTEINS - The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention. | 2021-06-17 |
20210177984 | Skin-Permeating Carrier Containing Nucleic Acid Complex and Use Thereof - A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface. | 2021-06-17 |
20210177985 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES - The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 2021-06-17 |
20210177986 | BI-FUNCTIONAL ALLOSTERIC PROTEIN-DRUG MOLECULES FOR TARGETED THERAPY - Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer. | 2021-06-17 |
20210177987 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER - The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer). | 2021-06-17 |
20210177988 | IMMUNOREACTANT CARRIER - An immunoreactive substance carrier according to an embodiment of the present invention may stably deliver various immunoreactive substances including antibodies and/or cytokines, to a target site, thereby exhibiting excellent immunotherapeutic effects. Therefore, a composition including the immunoreactive substance carrier can be used for immunotherapy, thereby having excellent effects in the prevention or treatment of cancer or various immune diseases. | 2021-06-17 |
20210177989 | Methods of Treating or Preventing Amyotrophic Lateral Sclerosis - This disclosure provides methods for treating, ameliorating, or reversing at least one symptom of amyotrophic lateral sclerosis (ALS) in a subject by increasing the amount of neuronal aspartate in spinal cord through administration of a therapeutically effective amount of a composition comprising a nucleic acid encoding ASPA or a functional fragment thereof. | 2021-06-17 |
20210177990 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF - Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases. | 2021-06-17 |
20210177991 | FRATAXIN EXPRESSION CONSTRUCTS - The invention provides polynucleotides, vectors and viruses expressing frataxin and methods of treating Friedreich's Ataxia. | 2021-06-17 |
20210177992 | ANTICANCER FLUORESCENT SUBSTANCE DERIVED FROM NATURAL MATERIALS - Provided is a composition for preventing or treating cancer, the composition including resveratrone, resveratrone glucoside, or a combination thereof as an active ingredient. | 2021-06-17 |
20210177993 | NEAR INFRARED FLUORESCENT DYES, FORMULATIONS AND RELATED METHODS - Provided herein is a pharmaceutical composition comprising an effective amount of cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH (LS838) or pharmaceutically acceptable salts thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier. Further provided are lyophilized products comprising a dye-conjugate and m methods for identifying compromised and for binding phosphorylated annexin A2 (pANXA2) protein in a biological sample using a composition described herein. | 2021-06-17 |
20210177994 | Compositions And Methods For Imaging A Cell - Disclosed are methods of imaging a cancer cell, the method comprising applying a first alternating electric field at a first frequency to the cancer cell for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cell for the first period of time increases permeability of cell membranes of the cancer cell; introducing a nanoparticle to the cancer cell, wherein the increased permeability of the cell membranes enables the nanoparticle to cross the cancer cell membrane; and imaging the cancer cell. | 2021-06-17 |
20210177995 | RADIOLABELLED mGluR2 PET LIGANDS - The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds. | 2021-06-17 |
20210177996 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER - The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib). | 2021-06-17 |
20210177997 | MICROSPHERES CONTAINING RADIOACTIVE ISOTOPES AND OTHER MARKERS AND ASSOCIATED METHODS - Multiphase microspheres for radioembolization include two-phase microspheres and three-phase microspheres prepared by a microfluidic process. The multiphase microspheres include a primary phase and a first secondary phase surrounded by the primary phase. The primary phase includes a first resin. The first secondary phase includes a second resin and at least one of a radioactive isotope or a compound including at least one radioactive element. Three-phase microspheres additionally include a second secondary phase discrete from the first secondary phase and also surrounded by the primary phase. The second secondary phase may be a gas such as air. The microspheres may be formed by a microfluidic process. | 2021-06-17 |
20210177998 | Internal Ultraviolet LED Antifouling - An internal ultraviolet-C light emitting diode antifouling system and method that include a waterproof, light transmissible potted enclosure; an object disposed within the waterproof, light transmissible potted enclosure; and at least one ultraviolet-C light emitting diode disposed within the waterproof, light transmissible enclosure, wherein the at least one ultraviolet-C light emitting diode is configured to emit light on the object, wherein the light is configured to prevent biofouling on the object. | 2021-06-17 |
20210177999 | ULTRAVIOLET RAY IRRADIATION DEVICE AND ULTRAVIOLET RAY BLOCKING UNIT - To provide an ultraviolet ray irradiation device by preventing leakage of ultraviolet rays from an insertion opening through which a hand on which a glove is mounted is inserted into a sterilization chamber. The device includes: an ultraviolet ray blocking balloon disposed in an insertion opening; a pressurized gas supplying and discharging device which supplies a gas under pressure to the balloon and discharges from it; an insertion depth detection unit which outputs an insertion hand depth detection signal; a controller of an ultraviolet ray irradiation and a pressurized gas supplying and discharging, wherein the balloon forms an opening which allows an insertion and a removal of the hand before the gas is supplied, and it is inflated with the supply of the gas so as to be brought into close contact with a wrist portion of the glove, and it is deflated with a discharge of the gas. | 2021-06-17 |
20210178000 | Hard-Surface Disinfection System - UV hard-surface disinfection system that is able to disinfect the hard surfaces in a room, while minimizing missed areas due to shadows by providing multiple UV light towers that can be placed in several areas of a room such that shadowed areas are eliminated and that can be transported by a cart that is low to the ground such that the towers may be loaded and unloaded easily by a single operator. The system is able to be controlled remotely, such that during activation of the system, no operator is present, and to automatically cut power to all towers in the event that a person enters the room. | 2021-06-17 |
20210178001 | SYSTEMS AND METHODS FOR DISINFECTION - A disinfecting system includes a housing. An ultraviolet light (UV) source is secured to the housing and configured to emit UV light for disinfection of a target. A processor is secured to the housing in communication with the UV light source. The processor is configured to activate the UV light source for a selected amount of time suitable for disinfection of the target. | 2021-06-17 |
20210178002 | STERILITY-PRESERVING ROBOTIC FRONTEND-SYSTEM - A sterility-preserving robotic frontend-system, including a flexible trajectory-guide including at least one force- and/or torque-transmitting coupling-member, a baffle-member separating a sterile section from a non-sterile section, and a sterility-sleeve attached to the baffle-member; an actuator unit having a sensor unit that senses at least one of a) whether a trajectory-guide is placed with respect to the actuator unit in a manner that allows engaging-members to accurately engage an actuator interface, and b) whether the engaging-members have accurately engaged the actuator-interface; and a retainer-receptacle adapted to temporarily accommodate the trajectory guide, and to restrain flexibility of the trajectory-guide while it is accommodated. A packaging-container having an inner sterile volume containing the retainer-receptacle and the trajectory-guide and a method of setting up such a sterility-preserving robotic frontend-system. | 2021-06-17 |
20210178003 | SCENTED ELECTRONIC CANDLE - Methods, systems and devices associated with a scented electronic candle are described. In one example, an electronic candle includes an outer shell with one or more openings configured to allow a fragrance to exit to an ambient environment of the electronic candle. The outer shell comprises a central opening such that a flame element protrudes at least partially through the central opening. The device includes a light emitting component to emit a light onto the movable flame, and a mounting base positioned below the movable flame element. The device also includes a scent storage component removably coupled to the mounting base. The scent storage component includes a container to store a fragrance and an absorption member configured to draw the fragrance to the ambient environment of the electronic candle through the one or more small openings of the outer shell. | 2021-06-17 |
20210178004 | Multi-chambered and extended release fragrance and scenting devices - This invention is an air freshener, one that can be applied to consecutively disseminate scented material into the air, and includes a base member, the base member having a plurality of chambers or cavities provided therein, and into which a fragrance emitting gel may be deposited, during manufacture, with each cavity having a seal member applied thereon, to seal in the gel material. Then, the seal members may be removed consecutively, or in certain instances simultaneously, in order to disseminate the air freshening material from the contained gel to provide for the admittance of fragrance aroma into the surrounding atmosphere. In another embodiment, the base member may have a series of laminates applied to it, each laminate having a fragrance emitting material applied thereto, so that as each laminate is removed, it provides for a sustained emission of a fragrance aroma into the surrounding atmosphere, to function as an air freshener. The base members may be suspended by a cord from a support, whether it be in the vehicle, an office, or a room in the home. | 2021-06-17 |
20210178005 | ARTICLES FORMED OF PULP BASE MATERIALS WITH MODULATED SCENT RELEASE - Described are articles formed of a pulp base material comprising fibers, wherein pores are formed between the fibers. A volatile composition with at least one top note component and at least one base note component at least partially fills the pores of the pulp base material. A release rate of the at least one top note component is modulated by the pulp base material, and a release rate of the at least one base note component is enhanced by the pulp base material. | 2021-06-17 |
20210178006 | AROMATHERAPY DEVICE - An aromatherapy device comprises a housing and an atomizing device configured for atomizing essential oil to be sprayed out, the housing is provided with a receiving chamber configured for fittingly receiving the atomizing device, and the receiving chamber is provided therein with an pop-up mechanism configured for launching the atomizing device out. The aromatherapy device provided in the present application is provided with a receiving chamber in the housing, and the receiving chamber is used to receive the atomizing device, such that the atomizing device can be quickly hidden inside the receiving chamber when used, and the atomizing device can be detachably connected to the housing to prevent the atomizing device from being damaged by touching. | 2021-06-17 |
20210178007 | Air purification device able to kill bacteria and viruses - An air purification device able to kill bacteria and viruses is provided, including an air channel, an air pump, a filtering device, and an electrodeless ultraviolet sterilization device. The electrodeless ultraviolet sterilization device is arranged inside the air channel and includes a microwave generator, an electrodeless ultraviolet tube, and a uniform radiator. The uniform radiator is a coaxial cable with gaps provided thereon. The electrodeless ultraviolet tube is a hollow columnar quartz tube. The coaxial cable is arranged in a hollow portion of the quartz tube. The coaxial cable is connected to the to microwave generator. The air purification device has a compact structure. Through arranging the electrodeless ultraviolet sterilization device inside the air channel, large-granular dust in the air is filtered, and meanwhile, bacteria and viruses in the air are effectively killed. Moreover, the present invention is safe and effective and has high sterilization efficiency and a low production cost. | 2021-06-17 |
20210178008 | MULTI-FUNCTIONAL LIGHTING FIXTURE - A lighting fixture includes a first compartment including a light sealed air plenum and a first lighting source arranged in the plenum to irradiate passing air through the plenum to destroy pathogens. A second compartment is configured to be external to the first compartment. A second lighting source is arranged in the second compartment to illuminate an area adjacent to the second compartment. | 2021-06-17 |
20210178009 | WOUND CARE PRODUCTS COMPRISING ALEXIDINE - A wound care product and related methods of treatment for wound site infection and for healing a wound is disclosed. The wound care product includes alexidine and a substrate and/or a pharmaceutically acceptable carrier. | 2021-06-17 |
20210178010 | BIOACTIVE WOUND DRESSING - A cost effective bacterial cellulose wound dressing includes a microbial-derived cellulose loaded with natural antibacterial and regenerative substances. This wound dressing is effective for the treatment of burns and chronic wounds. The dressing keeps the wound moist while absorbing exudates from the wound area. The dressings possess antibacterial qualities to protect the wound from infections and help the area to heal faster through the action of bioactive substances. | 2021-06-17 |
20210178011 | HEMOSTATIC DEVICES - Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon. | 2021-06-17 |
20210178012 | FOAM WOUND DRESSING COMPRISING AN ANTISEPTIC - An open-cell foam wound dressing comprising a formulation of an amphiphilic antiseptic and particular surfactants is provided. | 2021-06-17 |
20210178013 | HEMOSTATIC DEVICES - A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate. | 2021-06-17 |
20210178014 | ENDOSCOPE HEMOSTATIC MATERIAL - The present invention is an endoscope hemostatic material comprising a sheet-like nonwoven fabric that is formed from a hydrophobic material that has a bulk density of 40 to 110 mg/cm | 2021-06-17 |
20210178015 | METHOD TO PRODUCE A PROSTHETIC COMPONENT, AND PROSTHETIC COMPONENT THUS PRODUCED - Method to produce a single-piece prosthetic component ( | 2021-06-17 |
20210178016 | IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONS - A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures. | 2021-06-17 |
20210178017 | MULTI-LAYER BIOMATERIAL FOR TISSUE REGENERATION AND WOUND HEALING - The technology described herein is directed to compositions comprising at least a first porous biomaterial layer and a second impermeable biomaterial layer and methods relating thereto. In some embodiments, the compositions and methods described herein relate to wound healing, e.g. repair of wounds and/or tissue defects. | 2021-06-17 |
20210178018 | SILK/PET MIX-WOVEN SCAFFOLD AND PREPARATION METHOD AND USE THEREOF - The present invention relates to the technical field of silk scaffolds, and in particular, to a silk/pet mix-woven scaffold and a preparation method and use thereof. The silk/PET mix-woven scaffold is formed by weaving silk and PET fibers. Sericin of the silk is removed. The silk and the PET fibers are mixed and knitted. The PET fibers provide reliable fixation in an early stage to maintain the stability of mechanical properties, and the silk degrades gradually in a later stage to promote the growth of new tissues to achieve the integration of the scaffold and the body. When the scaffold is used for artificial tendon/ligament recovery, its overall performance is better than that of pure silk or pure PET fiber scaffolds, and the scaffold has excellent clinical transformation potential. | 2021-06-17 |
20210178019 | JOINT SPACERS - A joint spacer is provided for treatment of a joint of a human subject, the joint spacer including a pouch having a wall including a dermal graft material. The joint spacer is configured to be inserted into a space of the joint, and is shaped, when the pouch is inserted into the space and filled, to provide mechanical support to the joint. Other embodiments are also described. | 2021-06-17 |